Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Precipio seeks more accurate cancer diagnoses

There’s a better way to do cancer diagnostics, says Precipio DiagnosticsCEO Ilan Danieli. He points a finger at existing methodologies that stress cost saving over accuracy. While...

| By Kelley Gipson

ReNetX focuses on spinal cord injury patients

ReNetX Bio’s NoGo Trap therapeutic has been given “fast track” status by the Food and Drug Administration. The firm’s mission statement is clear and precise:...

| By Kelley Gipson

Per Hellsund leads Cybrexa anti-tumor effort

As a co-founder of Cybrexa, Per Hellsund rejoined old colleagues Kevin Didden, Cybrexa board chair, and Kevin Rakin, a director. They are seeking to leverage research developed...

| By Kelley Gipson

Led by Rosen, Artizan takes aim at inflammation

When James Rosen became president and CEO of Artizan Biosciences, it was a clear signal that Artizan was onto something big. Artizan’s initial product uses...

| By Kelley Gipson

UConn research funding surges to record levels

UConn has hit an impressive new high in external research funding, with its faculty attracting more than $375 million in new awards in the past...

| By Kelley Gipson

Boehringer Ingelheim acquires Abexxa Biologics

Boehringer Ingelheim reports the acquisition of Abexxa Biologics, a Texas biotech. “The acquisition of Abexxa bolsters our commitment to tumor-antigen discovery and new ways of...

| By Kelley Gipson

US News names top CT schools

Several Connecticut colleges and universities made U.S. News and World Report’s annual list of best colleges. UConn again ranks among top 25 national public universities...

| By Kelley Gipson

Sema4 names Stolovitzky Chief Science Officer

Sema4 has appointed Gustavo Stolovitzky, PhD, to the newly established senior leadership position of Chief Science Officer. Dr. Stolovitzky is a world-renowned expert in computational...